Enter AMYRA Biotech AG, a private Swiss company that has developed novel enzymatic solutions for both NCGS and CeD via a unique combination of recombinant exopeptidases that destroy the ...
This loss has important and potentially long-lasting implications for patient nutrition and quality of life,” said Erin Bonner, PhD, lead author of the publication and Senior Scientist at AMYRA ...
This loss has important and potentially long-lasting implications for patient nutrition and quality of life,” said Erin Bonner, PhD, lead author of the publication and Senior Scientist at AMYRA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback